Table 3.
Number of patients in rPFS, PFS, and OS at 6, 12, and 24 months
| Outcome | 6 months | 12 months | 24 months | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cabazitaxel | Second ARTA | Difference | Cabazitaxel | Second ARTA | Difference | Cabazitaxel | Second ARTA | Difference | |
| rPFS (number of patients) | 58 | 36 | 22 | 27 | 9 | 18 | 6 | 4 | 2 |
| PFS, (number of patients)a | 36 | 16 | 21 | 10 | 3 | 7 | 0 | 0 | 0 |
| OS, (number of patients) | 86 | 81 | 5 | 56 | 45 | 12 | 25 | 9 | 16 |
| Hospitalization days | 112 | 138 | −26 | 206 | 250 | −44 | 297 | 351 | −54 |
| ICU days | 5 | 7 | −2 | 6 | 8 | −2 | 7 | 8 | −1 |
Abbreviations: ARTA androgen receptor-targeted agent, ICU intensive care unit, OS overall survival, PFS progression-free survival, rPFS radiographic progression free survival
Values correspond to a cohort of 100 patients for each treatment
aNo results available for 24 months as the number at risk for PFS was 0 for both arms in the CARD trial